172 related articles for article (PubMed ID: 33765222)
1. Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods.
Demus D; Jansen BC; Gardner RA; Urbanowicz PA; Wu H; Štambuk T; Juszczak A; Medvidović EP; Juge N; Gornik O; Owen KR; Spencer DIR
Glycoconj J; 2021 Jun; 38(3):375-386. PubMed ID: 33765222
[TBL] [Abstract][Full Text] [Related]
2. Mutations in HNF1A result in marked alterations of plasma glycan profile.
Thanabalasingham G; Huffman JE; Kattla JJ; Novokmet M; Rudan I; Gloyn AL; Hayward C; Adamczyk B; Reynolds RM; Muzinic A; Hassanali N; Pucic M; Bennett AJ; Essafi A; Polasek O; Mughal SA; Redzic I; Primorac D; Zgaga L; Kolcic I; Hansen T; Gasperikova D; Tjora E; Strachan MW; Nielsen T; Stanik J; Klimes I; Pedersen OB; Njølstad PR; Wild SH; Gyllensten U; Gornik O; Wilson JF; Hastie ND; Campbell H; McCarthy MI; Rudd PM; Owen KR; Lauc G; Wright AF
Diabetes; 2013 Apr; 62(4):1329-37. PubMed ID: 23274891
[TBL] [Abstract][Full Text] [Related]
3. Development of an exoglycosidase plate-based assay for detecting α1-3,4 fucosylation biomarker in individuals with HNF1A-MODY.
Demus D; Urbanowicz PA; Gardner RA; Wu H; Juszczak A; Štambuk T; Medvidović EP; Owen KR; Gornik O; Juge N; Spencer DIR
Glycobiology; 2022 Mar; 32(3):230-238. PubMed ID: 34939081
[TBL] [Abstract][Full Text] [Related]
4. Fucosylated AGP glycopeptides as biomarkers of HNF1A-Maturity onset diabetes of the young.
Tijardović M; Štambuk T; Juszczak A; Keser T; Gasperikova D; Novokmet M; Tjora E; Pape Medvidović E; Stanik J; Rasmus Njølstad P; Lauc G; Owen KR; Gornik O
Diabetes Res Clin Pract; 2022 Mar; 185():109226. PubMed ID: 35122907
[TBL] [Abstract][Full Text] [Related]
5. Plasma Fucosylated Glycans and C-Reactive Protein as Biomarkers of HNF1A-MODY in Young Adult-Onset Nonautoimmune Diabetes.
Juszczak A; Pavić T; Vučković F; Bennett AJ; Shah N; Pape Medvidović E; Groves CJ; Šekerija M; Chandler K; Burrows C; Rojnić Putarek N; Vučić Lovrenčić M; Ćuća Knežević J; James TJ; Gloyn AL; Lauc G; McCarthy MI; Owen KR; Gornik O
Diabetes Care; 2019 Jan; 42(1):17-26. PubMed ID: 30455330
[TBL] [Abstract][Full Text] [Related]
6. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
Besser RE; Shepherd MH; McDonald TJ; Shields BM; Knight BA; Ellard S; Hattersley AT
Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
[TBL] [Abstract][Full Text] [Related]
7. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
Owen KR; Thanabalasingham G; James TJ; Karpe F; Farmer AJ; McCarthy MI; Gloyn AL
Diabetes Care; 2010 Sep; 33(9):1919-24. PubMed ID: 20724646
[TBL] [Abstract][Full Text] [Related]
8. Liver adenomatosis in patients with hepatocyte nuclear factor-1 alpha maturity onset diabetes of the young (HNF1A-MODY): Clinical, radiological and pathological characteristics in a French series.
Haddouche A; Bellanne-Chantelot C; Rod A; Fournier L; Chiche L; Gautier JF; Timsit J; Laboureau S; Chaillous L; Valero R; Larger E; Jeandidier N; Wilhelm JM; Popelier M; Guillausseau PJ; Thivolet C; Lecomte P; Benhamou PY; Reznik Y
J Diabetes; 2020 Jan; 12(1):48-57. PubMed ID: 31166087
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
Mughal SA; Park R; Nowak N; Gloyn AL; Karpe F; Matile H; Malecki MT; McCarthy MI; Stoffel M; Owen KR
Diabet Med; 2013 Feb; 30(2):246-50. PubMed ID: 23157689
[TBL] [Abstract][Full Text] [Related]
10. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
[TBL] [Abstract][Full Text] [Related]
11. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
Thanabalasingham G; Shah N; Vaxillaire M; Hansen T; Tuomi T; Gašperíková D; Szopa M; Tjora E; James TJ; Kokko P; Loiseleur F; Andersson E; Gaget S; Isomaa B; Nowak N; Raeder H; Stanik J; Njolstad PR; Malecki MT; Klimes I; Groop L; Pedersen O; Froguel P; McCarthy MI; Gloyn AL; Owen KR
Diabetologia; 2011 Nov; 54(11):2801-10. PubMed ID: 21814873
[TBL] [Abstract][Full Text] [Related]
12. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
Kyithar MP; Bacon S; Pannu KK; Rizvi SR; Colclough K; Ellard S; Byrne MM
Diabetes Metab; 2011 Dec; 37(6):512-9. PubMed ID: 21683639
[TBL] [Abstract][Full Text] [Related]
13. Functional Analyses of HNF1A-MODY Variants Refine the Interpretation of Identified Sequence Variants.
Malikova J; Kaci A; Dusatkova P; Aukrust I; Torsvik J; Vesela K; Kankova PD; Njølstad PR; Pruhova S; Bjørkhaug L
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 32017842
[TBL] [Abstract][Full Text] [Related]
14. Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients.
Szopa M; Osmenda G; Wilk G; Matejko B; Skupien J; Zapala B; Młynarski W; Guzik T; Malecki MT
Eur J Endocrinol; 2015 Mar; 172(3):277-83. PubMed ID: 25501962
[TBL] [Abstract][Full Text] [Related]
15. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
[TBL] [Abstract][Full Text] [Related]
16. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations.
Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L
Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271
[TBL] [Abstract][Full Text] [Related]
17. Effects of hepatocyte nuclear factor-1A and -4A on pancreatic stone protein/regenerating protein and C-reactive protein gene expression: implications for maturity-onset diabetes of the young.
Kyithar MP; Bonner C; Bacon S; Kilbride SM; Schmid J; Graf R; Prehn JH; Byrne MM
J Transl Med; 2013 Jun; 11():156. PubMed ID: 23803251
[TBL] [Abstract][Full Text] [Related]
18. The Common
Locke JM; Saint-Martin C; Laver TW; Patel KA; Wood AR; Sharp SA; Ellard S; Bellanné-Chantelot C; Hattersley AT; Harries LW; Weedon MN
Diabetes; 2018 Sep; 67(9):1903-1907. PubMed ID: 29895593
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of HNF1A variants in paediatric diabetes in Norway using functional and clinical investigations to unmask phenotype and monogenic diabetes.
Svalastoga P; Kaci A; Molnes J; Solheim MH; Johansson BB; Krogvold L; Skrivarhaug T; Valen E; Johansson S; Molven A; Sagen JV; Søfteland E; Bjørkhaug L; Tjora E; Aukrust I; Njølstad PR
Diabetologia; 2023 Dec; 66(12):2226-2237. PubMed ID: 37798422
[TBL] [Abstract][Full Text] [Related]
20. Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model.
Urbanova J; Andel M; Potockova J; Klima J; Macek J; Ptacek P; Mat'oska V; Kumstyrova T; Heneberg P
Curr Pharm Des; 2015; 21(39):5736-48. PubMed ID: 26446475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
